Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523913 | 0.92 | TSHR (0.39) | DUTALDH1A1TSHRHRH4HRH3 | |
| SCHEMBL31283347 | 0.92 | DUT (0.38) | DUT | |
| SCHEMBL1803181 | 0.88 | HTR1B (0.31) | DUT | |
| SCHEMBL17520284 | 0.87 | TSHR (0.43) | DUTALDH1A1TSHRHRH4HRH3 | |
| SCHEMBL24387070 | 0.85 | CA12 (0.41) | DUTALDH1A1TSHRMEN1CYP2C19 | |
| SCHEMBL31024461 | 0.83 | CA12 (0.43) | DUTTSHRPAOXMEN1CYP2C19 | |
| SCHEMBL19543533 | 0.80 | DUT (0.35) | DUTALDH1A1TSHR | |
| SCHEMBL1317211 | 0.79 | ADRB2 (0.42) | DUTALDH1A1TSHRCYP2C19 | |
| SCHEMBL844556 | 0.79 | DUT (0.33) | DUT | |
| SCHEMBL16257046 | 0.78 | DUT (0.33) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207930-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3159337-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2663555-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2467380-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9242964-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2663555-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012097177-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2467380-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011022509-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | DUT 3940/4885ALDH1A1 1667/4885TSHR 2731/4885 |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | DUT 3940/4885ALDH1A1 1667/4885TSHR 2731/4885 |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | DUT 3940/4885ALDH1A1 1667/4885TSHR 2731/4885 |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | DUT 3979/4885ALDH1A1 2203/4885TSHR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.